Identifying and addressing physicians’ differing views on the ‘right experience’ has become one of the top priorities for pharma & biotech companies implementing new commercial models.
With the transition of traditional sales and marketing approaches to customer centric service models, pharmaceutical and biotechnology companies are seeking out best practice approaches of how to meet the doctors’ need for product, disease state, and reimbursement information. Physicians want fewer, but stronger, relationships with company representatives who can provide more valuable information, deliver more relevant services, and better respond to specific needs of the practice, as the recent IMS Health study reveals.
What are the new approaches and tools for gaining better access to physicians? How can SFE be measured in new commercial models? What are the alternative sales channels to engage with your customers more effectively? Are you looking for the right answers?
Gaining better access to doctors and new customer segments physician centric model will be discussed in detail at the upcoming Fleming Europe’s 8th Annual Global Pharma SFE Forum.
In his case study, Mr. Conor Doyle, Sales Manager at Merck & Co, will present examples of segmentation, talk about alternative channels and targeting techniques to gain access to the doctors, and give advice on account-based models – how to apply a holistic approach to influence complex decision-making processes.
In order to achieve overall sales excellence, the 2013 event will introduce a brand new strategy – interacting activities and joining forces of sales, marketing, CRM, HR, and Sales training & development.
Corey Bouwman, Sales & Marketing Director at Chiesi, will focus on Chiesi College – Innovative model of collaboration with doctors. He will explain how to adapt a sales strategy in turbulent times, and give examples of tools and practices of new customer interactions and their implications for sales forces.
25+ expert speakers along with 100+ delegates from top pharma companies such as Pfizer, Roche, Eli Lilly, GSK, Johnson & Johnson, Bristol Myers Squibb, Merck & Co, Novartis, AstraZeneca, Sanofi, etc. will join the Global SFE Forum in Amsterdam on 14 – 15 February 2013.
The presence of Vice Presidents, Senior Directors, Senior Managers, CRM and SFA Specialists, and Key Account Managers from Europe, Russia, CEE region, Middle East and USA will contribute to a unique global SFE experience.
7 years, 7 editions and 700+ satisfied attendees stand behind the success of Fleming Europe’s SFE conferences. “To keep up with the bar raised already pretty high, the 2013 event will introduce its proven two-stream program covering more topics and three unique focused workshops. In order to help participants get to know each other more thoroughly, speed networking activity will be included in the morning of the first day,” revealed Dasa Laslopova, Conference Producer.
To find out more about the Fleming Europe’s Global SFE Forum, visit the event website.
About Fleming Europe
Established in Slovakia, Fleming Europe represents a Pan-European B2B networking channel for specialists to collect & share knowledge. Since 2004, the company has been encouraging decision makers in sharing their experiences through market leading conferences, trainings and webinars. The annual audience of 10,000 Banking, Defense, Energy, Oil & Gas, Pharma, Telco and Transport peers benefit from insights on industry trends when applying them to their own business practices. For more information visit http://flemingeurope.com/